secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001493152-24-001667
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix halts PUR1900 Ph2b study; Cipla assumes ex-US development for 2% royalty
--------------------------------------------------------------------------------

- Enrollment stopped at 8 subjects; study wind-down expected by July 2024; Pulmatrix's cash burn significantly reduced.
- Cipla gets exclusive rights to all markets outside the US; Pulmatrix receives 2% royalty on net sales in Cipla Territory.
- Cash on hand ~$19M as of Dec 31, 2023; cash runway extended into Q1 2026.
- CEO Teofilo Raad granted retention bonus of $170K/quarter for Q1 and Q2 2024, payable on employment conditions.
- Company retained MTS Health Partners to review strategic alternatives to maximize shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224001667/0001493152-24-001667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224001667/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-001667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer